Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 122 publications
Plasma EV Proteomics Identifies ECM Remodeling and Inflammatory Proteins LUM and C7 as Candidate Biomarkers in FSHD.
Journal: Annals of clinical and translational neurology
Published: April 27, 2026
In response to: Personalized antioxidant supplementation improves muscle strength, physical activity, and quality of life in patients with FSHD1: A real-world longitudinal study. Laoudj-Chenivesse D, Arbogast S, Raynaud De Mauverger E, Fedou C, Debroize E, Hugon G, Pincemail J, Picot MC, Cristol JP, Mercier J, Portet F. Free Radic Biol Med. 2026 Feb 28; 248: 424-435.
Journal: Free radical biology & medicine
Published: April 26, 2026
Prospective Study of Video Hand Opening Time as a Quantitative Measurement of Myotonia in Patients With Myotonic Dystrophy Type 1.
Journal: Neurology
Published: February 26, 2026
An Antibody-Oligonucleotide Conjugate for Myotonic Dystrophy Type 1.
Journal: The New England journal of medicine
Published: February 18, 2026
A randomized, double-blind, placebo-controlled study of losmapimod in patients with facioscapulohumeral muscular dystrophy: Results of the REACH study.
Journal: Journal of neuromuscular diseases
Published: February 06, 2026
Natural history of limb girdle muscular dystrophy R1 (LGMDR1): a GRASP consortium study.
Journal: Neuromuscular disorders : NMD
Published: December 10, 2025
Longitudinal Psychometric Properties of the Myotonic Dystrophy Health Index in a Large Multicenter Cohort of People Living With Myotonic Dystrophy Type 1.
Journal: Muscle & nerve
Published: December 05, 2025
Electrical Impedance Myography Detects Disease Progression over 12 to 24 Months in Facioscapulohumeral Muscular Dystrophy.
Journal: Annals of neurology
Published: November 14, 2025
Late-onset facioscapulohumeral muscular dystrophy defines a distinct clinical subgroup.
Journal: Neuromuscular disorders : NMD
Published: November 14, 2025
A pilot study using actigraphy to examine activity performance and its relationship with activity capacity in adults with facioscapulohumeral muscular dystrophy.
Journal: Journal of neuromuscular diseases
Published: October 21, 2025
Establishing biomarkers and clinical endpoints in myotonic dystrophy type 1 (END-DM1): Protocol of an international natural history study.
Journal: PloS one
Published: September 11, 2025
Confirmatory long-term efficacy and safety results of ataluren in patients with nmDMD from Study 041, an international, randomized, double-blind, placebo-controlled, Phase III trial.
Journal: Journal of comparative effectiveness research
Published: August 22, 2025
Last Updated: 09/26/2026